In their earlier papers (3,4) both the ADARC and Boston groups recognized the importance of such observations for HIV-specific immunity: the immune system must have sufficient levels of viral antigen (specifically those epitopes that induce the strongest responses) to maintain better control of the virus.
Both the ADARC and Boston researchers have implemented treatment interruptions in their study protocols involving patients treated during acute infection (within days of symptoms) or early infection (usually within several months of symptoms).